The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. In the field of gynecologic oncology, one major study that attracted considerable attention was expected to reshape the treatment landscape for advanced endometrial cancer in the later-line setting. The randomized, open-label, global phase III TroFuse-005 study (ENGOT-en23/GOG-3095) demonstrated that the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (Sac-TMT) significantly improved progression-free survival (PFS) and overall survival (OS) compared with treatment of physician's choice (TPC) in patients with previously treated advanced or recurrent endometrial cancer. The objective response rate (ORR) was nearly doubled, making Sac-TMT the first TROP2 ADC in this patient population to demonstrate improvements in both OS and PFS compared with chemotherapy.

During the congress, Oncology Frontier had the privilege of interviewing Professor Domenica Lorusso, Global Lead Investigator of TroFuse-005, Full Professor of Obstetrics and Gynecology at Humanitas University, Italy, and Head of Gynecologic Oncology at Humanitas San Pio X Hospital. The discussion explored the study design, efficacy findings, clinical positioning of TROP2 ADCs, safety management, and other notable studies presented at this year’s congress.

Study at a Glance: Key Findings from TroFuse-005

TroFuse-005 (ENGOT-en23/GOG-3095, NCT06132958) is a randomized, open-label, global phase III study with two primary endpoints: PFS and OS, both assessed by a blinded independent central review committee. ORR was the key secondary endpoint.

The study enrolled 776 patients with advanced or recurrent endometrial cancer, including carcinosarcoma, who had previously received platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, with no more than three prior lines of treatment. Patients were randomized 1:1 to receive either Sac-TMT (4 mg/kg once every two weeks) or TPC, consisting of doxorubicin (60 mg/m² once every three weeks) or paclitaxel (80 mg/m² on Days 1, 8, and 15 of each four-week cycle). The data cutoff date was March 23, 2026, with a median follow-up of 14.0 months.

Efficacy:

  • Median PFS: 7.2 months vs. 3.9 months (HR 0.59, 95% CI 0.50–0.70, P<0.0001), representing a 3.3-month improvement.
  • Median OS: 19.0 months vs. 12.1 months (HR 0.68, 95% CI 0.55–0.84, P=0.0001), representing a 6.9-month improvement.
  • ORR: 35.1% vs. 17.3% (difference of 17.8 percentage points, P<0.00001).
  • Median duration of response (DoR): 11.1 months vs. 6.9 months; the proportion of responses lasting ≥6 months was 69.0% vs. 53.2%.
  • Disease control rate (DCR): 74% vs. 57%.

Safety:

  • Incidence of grade ≥3 treatment-related adverse events (TRAEs): 54.4% vs. 41.4%.
  • Anemia was the most common adverse event in both groups (20.8% vs. 13.4%).
  • Treatment discontinuation due to TRAEs: 3.1% vs. 4.9%.
  • TRAE-related deaths: 0.8% vs. 0.8%.

Expert Interview

Oncology Frontier:

In TroFuse-005, what were the ORR and PFS results with sacituzumab tirumotecan (Sac-TMT) in previously treated advanced or recurrent endometrial cancer? How do these results compare with existing later-line treatment options?

Professor Domenica Lorusso: TroFuse-005 is a randomized phase III study evaluating the TROP2-targeted ADC sacituzumab tirumotecan against treatment of physician’s choice in patients with advanced or recurrent endometrial cancer whose disease had progressed following platinum-based chemotherapy and immunotherapy. The study had two primary endpoints, PFS and OS, with ORR as the key secondary endpoint. The study met all its endpoints.

Compared with standard chemotherapy, Sac-TMT reduced the risk of disease progression by 41%, with median PFS increasing from 3.9 months to 7.2 months. The risk of death was reduced by 32%, with median OS increasing from 12.1 months to 19 months. The proportion of patients achieving durable responses was doubled with Sac-TMT, increasing from 17.3% to 35.1%. The DCR was 74% versus 57%, and median DoR was 6.9 months versus 11.1 months.

Therefore, there is no doubt that this drug represents a new standard of care compared with standard chemotherapy.

Oncology Frontier:

What is the current clinical positioning of TROP2 ADCs in the later-line treatment of endometrial cancer? What directions are most worth exploring next?

Professor Domenica Lorusso: Sac-TMT is currently being investigated in combination with pembrolizumab in first-line patients with mismatch repair-proficient (pMMR) disease, with pembrolizumab monotherapy serving as the comparator. Therefore, the impressive later-line results from TroFuse-005 have moved this drug into the first-line setting. This is very likely to represent the future development pathway for Sac-TMT, as well as for all ADCs currently under clinical development for endometrial cancer.

Oncology Frontier:

How was the safety profile of Sac-TMT in TroFuse-005? Which adverse events should clinicians pay particular attention to in clinical practice?

Professor Domenica Lorusso: It is important to emphasize that the median treatment duration differed between the two groups: 31 weeks for patients receiving Sac-TMT compared with 15 weeks in the control group. Against this background, the incidence of grade ≥3 treatment-related adverse events was 54% in the Sac-TMT group versus 41% in the physician’s choice chemotherapy group.

However, the proportions of patients experiencing serious adverse events were very similar: 12% among patients receiving Sac-TMT and 14% in the control group. Treatment discontinuation rates were also comparable, at 3% and 5%, respectively.

What we observed in the Sac-TMT group was a higher proportion of dose interruptions (44% vs. 21%) and dose reductions (29% vs. 19%). Regarding specific adverse events, anemia was the most frequently reported hematologic toxicity, and it was predominantly grade 3 or lower. Stomatitis was the most frequently reported non-hematologic toxicity. Stomatitis of any grade was reported in 55% of patients receiving Sac-TMT compared with 15% in the control group. Most cases were grade 1–2, while grade 3 stomatitis was reported in 10% and 1.6% of patients, respectively.

Oncology Frontier:

Which study presented at this year’s ESMO Congress impressed you the most, and why?

Professor Domenica Lorusso: Without a doubt, it was TroFuse-005. It has changed the standard of care. This ADC has now become the new benchmark treatment and the comparator arm in clinical trials. It is therefore a truly important study, although it was not the only one.

Another important study presented in the Presidential Symposium was KEYNOTE-C93, which evaluated immunotherapy versus chemotherapy in patients with advanced or recurrent mismatch repair-deficient (dMMR) endometrial cancer. The results demonstrated a PFS benefit with immunotherapy. In my view, this is also a very important study because it offers an alternative based on immunotherapy monotherapy for patients with dMMR tumors who are unable or unwilling to receive chemotherapy.

Conclusion

From redefining the standard of care in later-line treatment, to exploring first-line combination strategies, and validating immunotherapy monotherapy as an alternative for patients with dMMR disease, the message from this year’s ESMO gynecologic oncology sessions was clear and consistent: the treatment landscape for advanced endometrial cancer is being rapidly reshaped, offering patients more options that are increasingly precise and manageable.

Following TroFuse-005, how TROP2 ADCs and immunotherapy will evolve in combination and complement one another in this therapeutic landscape is the next important question to watch.